Juthathip Mongkolsapaya

List of Publications by Citations

73 papers	8,834 citations	39 h-index	91 g-index
91 ext. papers	12,957 ext. citations	22.6 avg, IF	5.77 L-index

#	Paper	IF	Citations
73	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. *Nature Immunology*, **2016**, 17, 1102-8	19.1	637
72	Cross-reacting antibodies enhance dengue virus infection in humans. *Science*, **2010**, 328, 745-8	33.3	624
71	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature Immunology*, **2020**, 21, 1336-1345	19.1	615
70	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. *Nature Medicine*, **2003**, 9, 921-7	50.5	609
69	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell*, **2021**, 184, 2348-2361.e6	56.2	549
68	Structural basis of potent Zika-dengue virus antibody cross-neutralization. *Nature*, **2016**, 536, 48-53	50.4	362
67	T cell responses to whole SARS coronavirus in humans. *Journal of Immunology*, **2008**, 181, 5490-500	5.3	344
66	A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. *Nature Immunology*, **2015**, 16, 170-177	19.1	309
65	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*, **2021**, 184, 4220-4236.e13	56.2	296
64	MAIT cells are activated during human viral infections. *Nature Communications*, **2016**, 7, 11653	17.4	283
63	Antibody evasion by the P.1 strain of SARS-CoV-2. *Cell*, **2021**, 184, 2939-2954.e9	56.2	281
62	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell*, **2021**, 184, 2201-2211.e7	56.2	269
61	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. *Nature*, **2015**, 520, 109-13	50.4	234
60	Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. *Nature Structural Biology*, **1999**, 6, 1048-53		214
59	New insights into the immunopathology and control of dengue virus infection. *Nature Reviews Immunology*, **2015**, 15, 745-59	36.5	212
58	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infectious Diseases, The*, **2020**, 20, 1390-1400	25.5	212
57	T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. *Journal of Immunology*, **2006**, 176, 3821-9	5.3	210

56	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host and Microbe*, **2020**, 28, 445-454.e6	23.4	187
55	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. *Nature Structural and Molecular Biology*, **2020**, 27, 950-958	17.6	175
54	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. *Cell*, **2022**,	56.2	154
53	An in-depth analysis of original antigenic sin in dengue virus infection. *Journal of Virology*, **2011**, 85, 410-21	6.6	145
52	The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell*, **2021**, 184, 2183-2200.e22	56.2	145
51	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. *Wellcome Open Research*, **2020**, 5, 139	4.8	120
50	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.. *Lancet, The*, **2021**,	40	115
49	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. *Journal of Infectious Diseases*, **2018**, 218, 536-545	7	95
48	Antibodies and tuberculosis. *Tuberculosis*, **2016**, 101, 102-113	2.6	93
47	The immune response against flaviviruses. *Nature Immunology*, **2018**, 19, 1189-1198	19.1	82
46	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. *Nature Immunology*, **2017**, 18, 1261-1269	19.1	74
45	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet, The*, **2021**, 398, 981-990	40	68
44	Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. *Journal of Immunology*, **2012**, 188, 4971-9	5.3	65
43	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell*, **2021**, 184, 5699-5714.e11	56.2	64
42	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. *Nature Communications*, **2018**, 9, 2441	17.4	51
41	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. *Nature Communications*, **2017**, 8, 15411	17.4	48
40	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. *ACS Central Science*, **2021**, 7, 594-602	16.8	47
39	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.. *Lancet, The*, **2022**,	40	46

38	Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells. *PLoS Pathogens*, **2014**, 10, e1004434	7.6	43
37	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. *Transfusion Medicine*, **2021**, 31, 167-175	1.3	42
36	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. *Wellcome Open Research*, **2020**, 5, 181	4.8	38
35	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. *Eurosurveillance*, **2020**, 25,	19.8	36
34	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. *Nature Medicine*, **2018**, 24, 721-723	50.5	35
33	A simplified positive-sense-RNA virus construction approach that enhances analysis throughput. *Journal of Virology*, **2013**, 87, 12667-74	6.6	34
32	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. *Nature Immunology*, **2019**, 20, 1291-1298	19.1	33
31	Recent advances in understanding dengue. *F1000Research*, **2016**, 5,	3.6	31
30	Neutrophil Activation and Early Features of NET Formation Are Associated With Dengue Virus Infection in Human. *Frontiers in Immunology*, **2018**, 9, 3007	8.4	28
29	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. **2021**,		25
28	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. *Nature Communications*, **2021**, 12, 1951	17.4	25
27	Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8 T cell response. *Nature Immunology*, **2017**, 18, 1228-1237	19.1	22
26	The immunopathology of dengue and Zika virus infections. *Current Opinion in Immunology*, **2017**, 48, 1-6	7.8	22
25	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. *Nature Immunology*, **2018**, 19, 1248-1256	19.1	21
24	An immunodominant NP-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. *Nature Immunology*, **2021**,	19.1	19
23	Invariant NKT cell response to dengue virus infection in human. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2955	4.8	16
22	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. *Nature Communications*, **2020**, 11, 5278	17.4	16
21	The immunology of Zika Virus. *F1000Research*, **2018**, 7, 203	3.6	15

20	Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. *Journal of Virology*, **2018**, 92,	6.6	15
19	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. *Cell Host and Microbe*, **2021**,	23.4	14
18	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
17	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. *Nature Communications*, **2021**, 12, 6250	17.4	13
16	Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine **2021**,		13
15	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	12
14	Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins. *Nature Communications*, **2021**, 12, 1238	17.4	12
13	T cell Responses and Dengue Haemorrhagic Fever. *Novartis Foundation Symposium*, **2008**, 164-176		11
12	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.. *Nature Medicine*, **2022**,	50.5	11
11	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. *Cell Reports*, **2019**, 26, 1585-1597.e4	10.6	9
10	Autoantibody-dependent amplification of inflammation in SLE. *Cell Death and Disease*, **2020**, 11, 729	9.8	9
9	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. *Vaccines*, **2020**, 8,	5.3	8
8	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies		8
7	Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.. *Journal of Infectious Diseases*, **2022**,	7	7
6	Evolution of neurovirulent Zika virus. *Science*, **2017**, 358, 863-864	33.3	6
5	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2		6
4	The epitope arrangement on flavivirus particles contributes to Mab C10ʈs extraordinary neutralization breadth across Zika and dengue viruses. *Cell*, **2021**, 184, 6052-6066.e18	56.2	5
3	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.. *EBioMedicine*, **2022**, 77, 103902	8.8	5

2	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum	3
1	A high resolution view of an adolescent flavivirus	2